Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

46 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
COVID-19 infection in chronic myeloid leukaemia after one year of the pandemic in Italy. A Campus CML report.
Breccia M, Abruzzese E, Accurso V, Attolico I, Barulli S, Bergamaschi M, Binotto G, Bocchia M, Bonifacio M, Caocci G, Capodanno I, Castagnetti F, Cavazzini F, Crisà E, Crugnola M, Stella De Candia M, Elena C, Fava C, Galimberti S, Gozzini A, Gugliotta G, Intermesoli T, Iurlo A, La Barba G, Latagliata R, Leonetti Crescenzi S, Levato L, Loglisci G, Lucchesi A, Luciano L, Lunghi F, Luzi D, Malato A, Cristina Miggiano M, Pizzuti M, Pregno P, Rapezzi D, Rege-Cambrin G, Rosti G, Russo S, Sancetta R, Rita Scortechini A, Sorà F, Sportoletti P, Stagno F, Tafuri A, Tiribelli M, Foà R, Saglio G. Breccia M, et al. Among authors: loglisci g. Br J Haematol. 2022 Feb;196(3):559-565. doi: 10.1111/bjh.17890. Epub 2021 Oct 11. Br J Haematol. 2022. PMID: 34636033 Free PMC article.
Reduction of imatinib dose and persistence of complete molecular response after p210 multipeptide vaccine in chronic myeloid leukaemia treated with dose escalation for acquired resistance.
Breccia M, Bocchia M, Cannella L, Defina M, Ippoliti M, Loglisci G, Santopietro M, Lauria F, Alimena G. Breccia M, et al. Among authors: loglisci g. Br J Haematol. 2010 Jul;150(2):240-2. doi: 10.1111/j.1365-2141.2010.08187.x. Epub 2010 Mar 19. Br J Haematol. 2010. PMID: 20346015 Free article. No abstract available.
"Real-life" results of front-line treatment with Imatinib in older patients (≥ 65 years) with newly diagnosed chronic myelogenous leukemia.
Latagliata R, Breccia M, Carmosino I, Cannella L, De Cuia R, Diverio D, Frustaci A, Loglisci G, Mancini M, Santopietro M, Stefanizzi C, Volpicelli P, Vozella F, Alimena G. Latagliata R, et al. Among authors: loglisci g. Leuk Res. 2010 Nov;34(11):1472-5. doi: 10.1016/j.leukres.2010.07.001. Epub 2010 Aug 13. Leuk Res. 2010. PMID: 20708799
Suboptimal response to imatinib according to 2006-2009 European LeukaemiaNet criteria: a 'grey zone' at 3, 6 and 12 months identifies chronic myeloid leukaemia patients who need early intervention.
Breccia M, Orlandi SM, Latagliata R, Grammatico S, Diverio D, Mancini M, Loglisci G, Salaroli A, Federico V, Santopietro M, Alimena G. Breccia M, et al. Among authors: loglisci g. Br J Haematol. 2011 Jan;152(1):119-21. doi: 10.1111/j.1365-2141.2010.08380.x. Epub 2010 Oct 11. Br J Haematol. 2011. PMID: 21029071 Free article. No abstract available.
Low incidence rate of opportunistic and viral infections during imatinib treatment in chronic myeloid leukemia patients in early and late chronic phase.
Breccia M, Girmenia C, Latagliata R, Loglisci G, Santopietro M, Federico V, Petrucci L, Serrao A, Salaroli A, Alimena G. Breccia M, et al. Among authors: loglisci g. Mediterr J Hematol Infect Dis. 2011;3(1):e2011021. doi: 10.4084/MJHID.2011.021. Epub 2011 May 16. Mediterr J Hematol Infect Dis. 2011. PMID: 21713076 Free PMC article.
46 results